|
Outcome
|
Micafungin
|
Liposomal amphotericin B
|
P valuea
|
Total
| |
|---|
| |
Non-ICU (n = 127)
|
ICU (n = 120)
|
Non-ICU (n = 136)
|
ICU (n = 110)
|
Non-ICU
|
ICU
|
Non-ICU (n = 263)
|
ICU (n = 230)
|
P value
|
|---|
|
Overall treatment success
|
108 (85.0)
|
75 (62.5)
|
98 (72.1)
|
73 (66.4)
|
0.0113*
|
0.5828
|
206 (78.3)
|
148 (64.3)
|
0.0006*
|
|
Mycological response
|
109 (85.8)
|
88 (73.3)
|
106 (77.9)
|
79 (71.8)
|
0.1115
|
0.8825
|
215 (81.7)
|
167 (72.6)
|
0.2371
|
|
All-cause mortality at day 8
|
6 (4.7)
|
25 (20.8)
|
14 (10.3)
|
18 (16.4)
|
0.1057
|
0.4028
|
20 (7.6)
|
43 (18.7)
|
0.8935
|
|
All-cause mortality at day 30
|
25 (19.7)
|
46 (38.3)
|
32 (23.5)
|
38 (34.5)
|
0.4589
|
0.5852
|
57 (21.7)
|
84 (36.5)
|
0.0003*
|
- Data presented as n (%). ICU, intensive care unit. aMicafungin versus liposomal amphotericin B. *Statistically significant.
